Treatment of Adult Soft Tissue Sarcomas: An Overview

被引：0
作者：
Samia Arifi
Rhizlan Belbaraka
Rabie Rahhali
Nabil Ismaili
机构：
[1] Sidi Mohamed Ben Abdellah University,Department of Medical Oncology, Hassan II University Hospital, Medical School
[2] Mohammed VI University Hospital,Department of Medical Oncology
[3] Regional Center of Oncology,Department of Medical Oncology
来源：
Rare Cancers and Therapy | 2015年 / 3卷 / 1-2期
关键词：
Chemotherapy; Radiotherapy; Soft tissue sarcoma; Surgery; Targeted therapy;
D O I：
10.1007/s40487-015-0011-x
中图分类号：
学科分类号：
摘要：
Sarcomas are uncommon malignancies accounting for about 1% of all adult malignancies. Sarcomas are a heterogeneous group of tumors which includes more than 100 different subtypes. Surgery is the mainstay therapy for localized disease. In selected patients the combination of surgery with radiotherapy achieves better local control and offers the best chance of cure. Systemic treatment including cytotoxic chemotherapy or targeted therapies remains the mainstay therapy for most patients with advanced disease. There are a wide variety of clinical situations, such that an individualized treatment plan must be defined by a multidisciplinary tumor board. Treatment decisions should take into consideration the histology, site of disease, stage, performance status, treatment goals, and the patient’s wishes. The management of patients should be carried out in a center with expertise in the treatment of sarcomas for optimal outcome. This review will cover the different treatment modalities of adult soft tissue sarcomas.
引用
收藏
页码：69 / 87
页数：18
相关论文
共 313 条
[31]  
Tepper J(1994)Synovial sarcoma. Uniform response of metastases to high dose ifosfamide Cancer 73 2506-83
[32]  
Glastein E(2004)Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at single institution Cancer 101 627-3150
[33]  
Rosenberg SA(2004)The impact of chemotherapy on the survival of patients with high grade primary extremity liposarcoma Ann Surg 240 686-1608
[34]  
Tepper J(2014)Effectiveness of regional hyperthermia with chemotherapy for high-risk retroperitoneal and abdominal soft-tissue sarcoma after complete surgical resection: a subgroup analysis of a randomized phase-III multicenter study Ann Surg 260 749-5274
[35]  
Glatskin E(2010)Neo-adjuvant chemotherapy alone or with regional hyperthermia for localized high risk soft tissue sarcoma: a randomised phase 3 multicentre study Lancet Oncol 11 561-1220
[36]  
Keus RB(1997)High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma result in a >90% response and limb preservation Cancer 79 1129-33
[37]  
Rutgers EJ(1996)Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectabe extremity soft tissue sarcomas: a multicenter trial J Clin Oncol 14 2653-2436
[38]  
Ho GH(2003)Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresctable soft tissue sarcoma of the extremities Cancer 98 1483-253
[39]  
Gortzak E(2006)Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma Cancer 106 1776-61
[40]  
Albus-lutter CE(2001)Neoadjuvant combined with regional hypertermia for locally advanced primary or recurrent high risk adult soft tissue sarcomas of adults: long term results of phase II study Eur J Cancer 37 1599-508
12345678910